In EGFR-mutant advanced NSCLC, a 2018 phase III trial comparing osimertinib with standard EGFR tyrosine kinase inhibitors demonstrated improvement in disease-free survival (DFS) in the overall population, as well as in both never-smokers and smokers. This evidence concerns the gene EGFR and non-small cell lung carcinoma.